PMID- 17804135
OWN - NLM
STAT- MEDLINE
DCOM- 20080502
LR  - 20151119
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 32
IP  - 1
DP  - 2008 Jan 1
TI  - Open-label study of s-citalopram therapy of chronic fatigue syndrome and 
      co-morbid major depressive disorder.
PG  - 100-6
AB  - OBJECTIVE: Chronic fatigue syndrome (CFS) is a debilitating disorder with 
      prominent symptoms of malaise, fatigue, myalgia, arthralgia, and impaired 
      concentration. The symptoms of CFS may often overlap those of Major Depressive 
      Disorder (MDD). Treatment of CFS has generally been disappointing. We 
      hypothesized that s-citalopram therapy may improve the symptoms of both disorders 
      in CFS patients with co-morbid depression. METHODS: 16 patients received 
      s-citalopram 10 mg to 20 mg daily for up to 12 weeks. Outcome measures of CFS 
      included the Chalder Fatigue Questionnaire (CFQ), the multi-dimensional Fatigue 
      Impact Scale (FIS), the CFS symptom rating (CFS-SR) 100 mm visual analogue scale, 
      and the clinical global impressions severity (CGI/S) and change (CGI/C) ratings. 
      Secondary outcomes of MDD included the Hamilton Depression Rating (HAM-D), Beck 
      Depression Inventory (BDI), and the CGI/S and CGI/C ratings of MDD. RESULTS: We 
      observed reductions in the mean CFQ score (p<0.0005), FIS score (p<0.0005), and 
      CGI/S (p<0.0005) and CGI/C (p<0.0005) ratings over time. There was a significant 
      improvement in 5 of the 8 CFS-SR symptoms: post-exertion malaise (p=0.001), 
      headaches (p<0.0005), un-refreshing sleep (p<0.0005), and impaired memory and 
      concentration (p<0.0005). There was also a reduction in mean HAM-D (p<0.0005), 
      BDI (p<0.0005), CGI/S (p=0.001) and CGI/C (p<0.0005) ratings of MDD. LIMITATIONS: 
      The sample size was limited and the study design was not double-blind or placebo 
      controlled. CONCLUSION: We observed a significant reduction in both CFS and 
      co-morbid MDD symptom severity ratings, and improvement in 5 of 8 core somatic 
      symptoms of CFS during s-citalopram therapy.
FAU - Amsterdam, Jay D
AU  - Amsterdam JD
AD  - Depression Research Unit, Department of Psychiatry, University of Pennsylvania 
      School of Medicine, Philadelphia, PA, United States. jamsterd@mail.med.upenn.edu
FAU - Shults, Justine
AU  - Shults J
FAU - Rutherford, Nancy
AU  - Rutherford N
LA  - eng
GR  - 5R01 CA096885-02/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20070803
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents, Second-Generation/*therapeutic use
MH  - Citalopram/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy/*epidemiology
MH  - Drug Evaluation
MH  - Fatigue Syndrome, Chronic/*drug therapy/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Time Factors
EDAT- 2007/09/07 09:00
MHDA- 2008/05/03 09:00
CRDT- 2007/09/07 09:00
PHST- 2006/11/30 00:00 [received]
PHST- 2007/07/19 00:00 [revised]
PHST- 2007/07/20 00:00 [accepted]
PHST- 2007/09/07 09:00 [pubmed]
PHST- 2008/05/03 09:00 [medline]
PHST- 2007/09/07 09:00 [entrez]
AID - S0278-5846(07)00259-X [pii]
AID - 10.1016/j.pnpbp.2007.07.019 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):100-6. doi: 
      10.1016/j.pnpbp.2007.07.019. Epub 2007 Aug 3.